Everest Medicines Announces Publication of Etrasimod's Asian Multicenter Phase III ENLIGHT UC study (ES101002) Results in The Lancet Gastroenterology & Hepatology

[ 메디채널 김갑성 기자 ] The published study results are from the ENLIGHT UC study (ES101002), a multicenter, randomized, double-blind and placebo-controlled Phase III trial of etrasimod conducted across Asia. The study included a 12-week induction phase followed by a 40-week maintenance phase and represents the largest pivotal Phase III study to date in Asian patients with moderately to severely active ulcerative colitis. The study results showed that, during both the 12-week induction phase and the 40-week maintenance phase, etrasimod demonstrated statistically significant and clinically meaningf

• 김갑성 기자
• 2025-10-09 13:10